Due to the regulation and modulation of various molecular targets involving inflammatory cytokines (SOCS-3, SOCS-5, IL-1β, IL-4, IL-6, IL-8, IL-13, MCP-1, CXCL-1, CXCL-2, and IFN-c), astragalin has immense research potential to be developed as a promising candidate in the treatment of AD. This evidence concerns the gene IL1B and Alzheimer disease.